AU2006240324B2 - Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse - Google Patents
Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse Download PDFInfo
- Publication number
- AU2006240324B2 AU2006240324B2 AU2006240324A AU2006240324A AU2006240324B2 AU 2006240324 B2 AU2006240324 B2 AU 2006240324B2 AU 2006240324 A AU2006240324 A AU 2006240324A AU 2006240324 A AU2006240324 A AU 2006240324A AU 2006240324 B2 AU2006240324 B2 AU 2006240324B2
- Authority
- AU
- Australia
- Prior art keywords
- patient
- flumazenil
- treatment
- day
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 156
- 108010062745 Chloride Channels Proteins 0.000 title claims abstract description 87
- 102000011045 Chloride Channels Human genes 0.000 title claims abstract description 87
- 208000011117 substance-related disease Diseases 0.000 title abstract description 52
- 201000009032 substance abuse Diseases 0.000 title abstract description 45
- 231100000736 substance abuse Toxicity 0.000 title abstract description 28
- 238000011282 treatment Methods 0.000 claims abstract description 259
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 claims abstract description 241
- 229960004381 flumazenil Drugs 0.000 claims abstract description 227
- 238000000034 method Methods 0.000 claims abstract description 167
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 150
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 126
- 229960000930 hydroxyzine Drugs 0.000 claims description 118
- 239000003814 drug Substances 0.000 claims description 107
- 229940079593 drug Drugs 0.000 claims description 97
- 229960002870 gabapentin Drugs 0.000 claims description 76
- 235000019156 vitamin B Nutrition 0.000 claims description 56
- 239000011720 vitamin B Substances 0.000 claims description 56
- 238000012544 monitoring process Methods 0.000 claims description 53
- 229940046001 vitamin b complex Drugs 0.000 claims description 40
- 238000002203 pretreatment Methods 0.000 claims description 35
- 238000002483 medication Methods 0.000 claims description 29
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 24
- 102000027484 GABAA receptors Human genes 0.000 claims description 24
- 108091008681 GABAA receptors Proteins 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 23
- 235000005911 diet Nutrition 0.000 claims description 17
- 230000037213 diet Effects 0.000 claims description 17
- 229930003270 Vitamin B Natural products 0.000 claims description 15
- 238000011156 evaluation Methods 0.000 claims description 15
- 229960001252 methamphetamine Drugs 0.000 claims description 14
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 14
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 13
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 13
- 230000036961 partial effect Effects 0.000 claims description 13
- 150000007942 carboxylates Chemical group 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 150000008065 acid anhydrides Chemical class 0.000 claims description 10
- 150000001263 acyl chlorides Chemical class 0.000 claims description 10
- 150000001299 aldehydes Chemical class 0.000 claims description 10
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 10
- 150000001336 alkenes Chemical class 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 150000001924 cycloalkanes Chemical class 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 150000002576 ketones Chemical class 0.000 claims description 10
- 150000002825 nitriles Chemical class 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 229940125516 allosteric modulator Drugs 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- -1 aide Chemical class 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 239000004031 partial agonist Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 235000005550 amino acid supplement Nutrition 0.000 claims description 3
- 238000009226 cognitive therapy Methods 0.000 claims 2
- 230000000052 comparative effect Effects 0.000 claims 2
- 238000009207 exercise therapy Methods 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 45
- 239000003368 psychostimulant agent Substances 0.000 abstract description 44
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract description 32
- 235000019788 craving Nutrition 0.000 abstract description 28
- 208000024891 symptom Diseases 0.000 abstract description 16
- 238000001802 infusion Methods 0.000 description 107
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 76
- 229960003495 thiamine Drugs 0.000 description 74
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 74
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 70
- 235000019157 thiamine Nutrition 0.000 description 70
- 239000011721 thiamine Substances 0.000 description 70
- 229940088594 vitamin Drugs 0.000 description 46
- 229930003231 vitamin Natural products 0.000 description 46
- 235000013343 vitamin Nutrition 0.000 description 46
- 239000011782 vitamin Substances 0.000 description 46
- 229940011671 vitamin b6 Drugs 0.000 description 38
- 235000008160 pyridoxine Nutrition 0.000 description 34
- 239000011677 pyridoxine Substances 0.000 description 34
- 208000007848 Alcoholism Diseases 0.000 description 32
- 150000003722 vitamin derivatives Chemical class 0.000 description 30
- 238000002560 therapeutic procedure Methods 0.000 description 25
- 201000007930 alcohol dependence Diseases 0.000 description 24
- 208000019901 Anxiety disease Diseases 0.000 description 22
- 229940049706 benzodiazepine Drugs 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 20
- 230000036506 anxiety Effects 0.000 description 18
- 230000003247 decreasing effect Effects 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 15
- 238000001990 intravenous administration Methods 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000009467 reduction Effects 0.000 description 15
- 231100000027 toxicology Toxicity 0.000 description 15
- 210000002700 urine Anatomy 0.000 description 15
- 208000029650 alcohol withdrawal Diseases 0.000 description 13
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 13
- 206010012335 Dependence Diseases 0.000 description 12
- 239000008156 Ringer's lactate solution Substances 0.000 description 12
- 230000001154 acute effect Effects 0.000 description 12
- 150000001557 benzodiazepines Chemical class 0.000 description 12
- 230000001419 dependent effect Effects 0.000 description 12
- 201000009277 hairy cell leukemia Diseases 0.000 description 12
- 230000035882 stress Effects 0.000 description 12
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 11
- 229940065779 atarax Drugs 0.000 description 11
- 229960004414 clomethiazole Drugs 0.000 description 11
- 230000001149 cognitive effect Effects 0.000 description 11
- 229940015509 gabapentin 300 mg Drugs 0.000 description 11
- 229940041701 gabapentin 600 mg Drugs 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 10
- 229960003638 dopamine Drugs 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 238000001784 detoxification Methods 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 230000001624 sedative effect Effects 0.000 description 9
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 8
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 229960004526 piracetam Drugs 0.000 description 8
- 239000000932 sedative agent Substances 0.000 description 8
- 206010010904 Convulsion Diseases 0.000 description 7
- 239000002249 anxiolytic agent Substances 0.000 description 7
- 229960003920 cocaine Drugs 0.000 description 7
- 230000001186 cumulative effect Effects 0.000 description 7
- 238000001647 drug administration Methods 0.000 description 7
- 230000007717 exclusion Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000001771 impaired effect Effects 0.000 description 7
- 238000007726 management method Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 206010001497 Agitation Diseases 0.000 description 6
- 206010044565 Tremor Diseases 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 238000013542 behavioral therapy Methods 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 235000021152 breakfast Nutrition 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 206010015037 epilepsy Diseases 0.000 description 6
- 229930195712 glutamate Natural products 0.000 description 6
- 238000001671 psychotherapy Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000021 stimulant Substances 0.000 description 6
- 206010039897 Sedation Diseases 0.000 description 5
- RMMPZDDLWLALLJ-UHFFFAOYSA-N Thermophillin Chemical compound COC1=CC(=O)C(OC)=CC1=O RMMPZDDLWLALLJ-UHFFFAOYSA-N 0.000 description 5
- 238000013019 agitation Methods 0.000 description 5
- 206010001584 alcohol abuse Diseases 0.000 description 5
- 208000025746 alcohol use disease Diseases 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229960002563 disulfiram Drugs 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 235000005974 protein supplement Nutrition 0.000 description 5
- 229940116540 protein supplement Drugs 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000036280 sedation Effects 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- AUZONCFQVSMFAP-UHFFFAOYSA-N tetraethylthiuram disulfide Natural products CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 5
- 229940097022 thiamine 100 mg Drugs 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 102100035785 Acyl-CoA-binding protein Human genes 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 101710088194 Dehydrogenase Proteins 0.000 description 4
- 108010039287 Diazepam Binding Inhibitor Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 229930003451 Vitamin B1 Natural products 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000000949 anxiolytic effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000003371 gabaergic effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 238000009597 pregnancy test Methods 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 235000010374 vitamin B1 Nutrition 0.000 description 4
- 239000011691 vitamin B1 Substances 0.000 description 4
- 235000019158 vitamin B6 Nutrition 0.000 description 4
- 239000011726 vitamin B6 Substances 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 229930003779 Vitamin B12 Natural products 0.000 description 3
- 206010048010 Withdrawal syndrome Diseases 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 229940124604 anti-psychotic medication Drugs 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 208000037849 arterial hypertension Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000011278 co-treatment Methods 0.000 description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 229940085047 disulfiram 250 mg Drugs 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229960002464 fluoxetine Drugs 0.000 description 3
- 230000000848 glutamatergic effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 231100000663 medical toxicology Toxicity 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000001242 postsynaptic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000036387 respiratory rate Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229940125723 sedative agent Drugs 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 201000006152 substance dependence Diseases 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 239000011715 vitamin B12 Substances 0.000 description 3
- 235000019163 vitamin B12 Nutrition 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 2
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 206010012373 Depressed level of consciousness Diseases 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 241001539473 Euphoria Species 0.000 description 2
- 206010015535 Euphoric mood Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000006264 Korsakoff syndrome Diseases 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 206010030124 Oedema peripheral Diseases 0.000 description 2
- 206010033864 Paranoia Diseases 0.000 description 2
- 208000027099 Paranoid disease Diseases 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 208000005428 Thiamine Deficiency Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000011360 adjunctive therapy Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 150000001555 benzenes Chemical class 0.000 description 2
- 239000000749 benzodiazepine receptor blocking agent Substances 0.000 description 2
- 239000000755 benzodiazepine receptor inverse stimulating agent Substances 0.000 description 2
- 208000002894 beriberi Diseases 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 229960002104 cyanocobalamin Drugs 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 206010013864 duodenitis Diseases 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- KLNFAMGHSZQYHR-UHFFFAOYSA-N imidazo[4,5-i][1,2]benzodiazepine Chemical class C1=CC=NN=C2C3=NC=NC3=CC=C21 KLNFAMGHSZQYHR-UHFFFAOYSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125425 inverse agonist Drugs 0.000 description 2
- 239000002555 ionophore Substances 0.000 description 2
- 230000000236 ionophoric effect Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 235000017924 poor diet Nutrition 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000004844 protein turnover Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 229940098196 romazicon Drugs 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical compound N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 description 1
- BCDMOBYAJQEXIL-UHFFFAOYSA-N 1h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid Chemical compound N1=CC2=CC=CC=C2N2CN=C(C(=O)O)C2=C1 BCDMOBYAJQEXIL-UHFFFAOYSA-N 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 101100284231 Caenorhabditis elegans his-24 gene Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010010219 Compulsions Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012225 Delirium tremens Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000569 acute exposure Toxicity 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000000338 anxiogenic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- PUSKHXMZPOMNTQ-UHFFFAOYSA-N ethyl 2,1,3-benzoselenadiazole-5-carboxylate Chemical compound CCOC(=O)C1=CC=C2N=[Se]=NC2=C1 PUSKHXMZPOMNTQ-UHFFFAOYSA-N 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 229940083609 fluoxetine 20 mg Drugs 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 208000011819 intense anxiety Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- NHMUJYOBLYTIKO-UHFFFAOYSA-L magnesium;[(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino]methanesulfonate Chemical compound [Mg+2].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1.O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 NHMUJYOBLYTIKO-UHFFFAOYSA-L 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 229940072228 neurontin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 229960003209 phenmetrazine Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- PYNUOAIJIQGACY-UHFFFAOYSA-N propylazanium;chloride Chemical compound Cl.CCCN PYNUOAIJIQGACY-UHFFFAOYSA-N 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 230000003304 psychophysiological effect Effects 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940005859 thiamine 250 mg Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940079707 vistaril Drugs 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/111,435 US20050192271A1 (en) | 2003-07-15 | 2005-04-21 | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| US11/111,435 | 2005-04-21 | ||
| PCT/US2006/013155 WO2006115743A2 (en) | 2005-04-21 | 2006-04-07 | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2006240324A1 AU2006240324A1 (en) | 2006-11-02 |
| AU2006240324B2 true AU2006240324B2 (en) | 2010-02-25 |
Family
ID=37215204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006240324A Ceased AU2006240324B2 (en) | 2005-04-21 | 2006-04-07 | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20050192271A1 (https=) |
| EP (1) | EP1742639B1 (https=) |
| JP (1) | JP2008536921A (https=) |
| KR (1) | KR20080004615A (https=) |
| CN (1) | CN101203225A (https=) |
| AT (1) | ATE539755T1 (https=) |
| AU (1) | AU2006240324B2 (https=) |
| BR (1) | BRPI0610038A2 (https=) |
| CA (1) | CA2605918A1 (https=) |
| CR (1) | CR9444A (https=) |
| IL (1) | IL186641A0 (https=) |
| MX (1) | MX2007012993A (https=) |
| NO (1) | NO20075562L (https=) |
| NZ (1) | NZ562585A (https=) |
| RU (1) | RU2007143053A (https=) |
| WO (1) | WO2006115743A2 (https=) |
| ZA (1) | ZA200709048B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| RU2468799C1 (ru) * | 2011-08-03 | 2012-12-10 | Общество с ограниченной ответственностью "Урал Крафт" | Способ купирования алкогольного абстинентного синдрома посредством блокады бензодиазепиновых рецепторов |
| WO2015054730A1 (en) * | 2013-10-14 | 2015-04-23 | Palmaya Pty Ltd | Compositions and methods of administering same |
| US20200143922A1 (en) * | 2016-06-03 | 2020-05-07 | Yale University | Methods and apparatus for predicting depression treatment outcomes |
| JP2021521103A (ja) * | 2018-04-06 | 2021-08-26 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 物質使用障害の処置におけるガボキサドールの使用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002064213A1 (es) * | 2001-02-15 | 2002-08-22 | Hythiam, Inc. | Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la dependencia de cocaina |
| US20040092509A1 (en) * | 2001-01-17 | 2004-05-13 | Hythiam, Inc. | Use of flumazenil in the production of a drug for the treatment of alcohol dependency |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028611A (en) * | 1989-06-29 | 1991-07-02 | The Regents Of The University Of Minnesota | Treatment for cocaine use |
| US5519017A (en) * | 1990-03-29 | 1996-05-21 | Lts Lohmann Therapie-Systeme Gmbh + Co. Kg | Pharmaceutic formulation for the treatment of alcoholism |
| SE9100860D0 (sv) * | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
| DE4123106A1 (de) * | 1991-07-09 | 1993-01-14 | Schering Ag | Arzneimittel zur behandlung von entzugssymptomen |
| US5229120A (en) * | 1992-02-05 | 1993-07-20 | Devincent James F | Treatment for cocaine abuse |
| US5792796A (en) * | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
| GB9420010D0 (en) * | 1994-10-01 | 1994-11-16 | Marck Sharp & Dohme Limited | Nucleic acids |
| ID26346A (id) * | 1998-03-31 | 2000-12-14 | Shionogi & Co | PROSES PEMBUATAN TURUNAN ASAM 5-HIDROKSIBENZO (b)TIOFEN-3-KARBOKSILAT |
| AU4100699A (en) | 1998-05-28 | 1999-12-13 | Sepracor, Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
| US6890951B2 (en) * | 1998-08-05 | 2005-05-10 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
| US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| US6339106B1 (en) * | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
| EP1133299A1 (en) * | 1998-11-23 | 2001-09-19 | Sepracor Inc. | 2-hydroxymethylolanzapine compositions and methods |
| US6489341B1 (en) * | 1999-06-02 | 2002-12-03 | Sepracor Inc. | Methods for the treatment of neuroleptic and related disorders using sertindole derivatives |
| US6399826B1 (en) * | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
| US6750235B1 (en) * | 1999-09-30 | 2004-06-15 | The General Hospital Corporation | Pramipexole as a treatment for cocaine craving |
| EP1125579A3 (en) * | 2000-01-18 | 2003-01-02 | Pfizer Products Inc. | Uses of agrp-melanocortin receptor binding modulating compounds |
| US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| US20020150632A1 (en) * | 2001-04-12 | 2002-10-17 | Nick Scott | Psychonutracological method for craving reduction in humans |
| FR2827172B1 (fr) * | 2001-07-13 | 2004-07-02 | Pf Medicament | Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides |
| US20030176456A1 (en) * | 2001-12-21 | 2003-09-18 | June Harry L. | Methods for reducing alcohol cravings in chronic alcoholics |
| US6740677B2 (en) * | 2002-08-19 | 2004-05-25 | Hong Xue | Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids |
| AU2004216360B2 (en) * | 2003-02-27 | 2009-09-17 | Eisai R & D Management Co., Ltd. | Pharmaceutical composition for treatment of drug dependence |
| CA2526101A1 (en) * | 2003-05-30 | 2004-12-23 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of nalmefene |
| JP2005332453A (ja) * | 2004-05-19 | 2005-12-02 | Hitachi Ltd | 情報再生装置及び情報再生方法 |
| US20060167723A1 (en) * | 2005-01-21 | 2006-07-27 | Berg L M | Method of treating dependencies |
| JP2008538748A (ja) | 2005-04-07 | 2008-11-06 | ハイシアム， インコーポレイテッド | 不安、物質乱用及び依存の予防のための改良型方法及び組成物 |
-
2005
- 2005-04-21 US US11/111,435 patent/US20050192271A1/en not_active Abandoned
-
2006
- 2006-04-07 AU AU2006240324A patent/AU2006240324B2/en not_active Ceased
- 2006-04-07 CN CNA2006800219633A patent/CN101203225A/zh active Pending
- 2006-04-07 KR KR1020077026998A patent/KR20080004615A/ko not_active Withdrawn
- 2006-04-07 BR BRPI0610038A patent/BRPI0610038A2/pt not_active IP Right Cessation
- 2006-04-07 MX MX2007012993A patent/MX2007012993A/es not_active Application Discontinuation
- 2006-04-07 EP EP06740763A patent/EP1742639B1/en not_active Expired - Lifetime
- 2006-04-07 WO PCT/US2006/013155 patent/WO2006115743A2/en not_active Ceased
- 2006-04-07 JP JP2008507703A patent/JP2008536921A/ja active Pending
- 2006-04-07 RU RU2007143053/15A patent/RU2007143053A/ru not_active Application Discontinuation
- 2006-04-07 AT AT06740763T patent/ATE539755T1/de active
- 2006-04-07 CA CA002605918A patent/CA2605918A1/en not_active Abandoned
- 2006-04-07 NZ NZ562585A patent/NZ562585A/en not_active IP Right Cessation
-
2007
- 2007-10-14 IL IL186641A patent/IL186641A0/en unknown
- 2007-10-16 CR CR9444A patent/CR9444A/es not_active Application Discontinuation
- 2007-10-19 ZA ZA200709048A patent/ZA200709048B/xx unknown
- 2007-11-05 NO NO20075562A patent/NO20075562L/no not_active Application Discontinuation
-
2008
- 2008-05-13 US US12/119,911 patent/US7863267B2/en not_active Expired - Lifetime
-
2009
- 2009-03-13 US US12/404,132 patent/US20090215751A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040092509A1 (en) * | 2001-01-17 | 2004-05-13 | Hythiam, Inc. | Use of flumazenil in the production of a drug for the treatment of alcohol dependency |
| WO2002064213A1 (es) * | 2001-02-15 | 2002-08-22 | Hythiam, Inc. | Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la dependencia de cocaina |
Non-Patent Citations (1)
| Title |
|---|
| Gerra et al. Current Therapeutic Research (1991) 50(1): 62-66 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1742639A2 (en) | 2007-01-17 |
| MX2007012993A (es) | 2008-03-11 |
| CA2605918A1 (en) | 2006-11-02 |
| NZ562585A (en) | 2010-04-30 |
| EP1742639A4 (en) | 2008-05-07 |
| CR9444A (es) | 2008-02-20 |
| US20050192271A1 (en) | 2005-09-01 |
| WO2006115743A3 (en) | 2007-06-28 |
| US20090215751A1 (en) | 2009-08-27 |
| US7863267B2 (en) | 2011-01-04 |
| CN101203225A (zh) | 2008-06-18 |
| US20080207599A1 (en) | 2008-08-28 |
| ZA200709048B (en) | 2008-09-25 |
| NO20075562L (no) | 2007-12-07 |
| BRPI0610038A2 (pt) | 2016-11-29 |
| AU2006240324A1 (en) | 2006-11-02 |
| JP2008536921A (ja) | 2008-09-11 |
| RU2007143053A (ru) | 2009-05-27 |
| EP1742639B1 (en) | 2012-01-04 |
| KR20080004615A (ko) | 2008-01-09 |
| ATE539755T1 (de) | 2012-01-15 |
| WO2006115743A2 (en) | 2006-11-02 |
| IL186641A0 (en) | 2008-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Swift | Medications and alcohol craving | |
| Cohn et al. | Double-blind comparison of buspirone and clorazepate in anxious outpatients | |
| US20080132492A1 (en) | Use of Flumazenil in the Production of a Drug for the Treatment of Alcohol Dependency | |
| Chitneni et al. | Use of ketamine infusions for treatment of complex regional pain syndrome: a systematic review | |
| US7863267B2 (en) | Use of selective chloride channel modulators to treat methamphetamine abuse | |
| Pabis et al. | Pharmacotherapy of aggressive behavior | |
| AU780817B2 (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone | |
| Polatin et al. | Integration of pharmacotherapy with psychological treatment of chronic pain | |
| WO2025175318A2 (en) | Pharmacotherapies for improving treatment adherence after discontinuation of incretin-based therapies | |
| US20060084659A1 (en) | Augmentation of psychotherapy with cannabinoid reuptake inhibitors | |
| JP2007529547A (ja) | アルコール中毒の処置方法 | |
| US20120270860A1 (en) | Methods for treating or preventing alcohol-related disorders or craving-related disorders | |
| US6979698B1 (en) | Method of treating cognitive deficits in learning and memory | |
| JP2019514978A (ja) | イブジラストを使用したアルコール依存症並びにうつ病及び／又は不快な気分の治療 | |
| Pavuluri et al. | Handbook of psychopharmacotherapy: a life-span approach | |
| Quinn et al. | Depression in patients with CKD and ESRD | |
| Pei et al. | Successful Rescue of Hypotension Shock Induced by Quetiapine: A Case Report | |
| US20180243251A1 (en) | Composition and Method for Improving Cognitive Function | |
| Mohatt et al. | Psychopharmacology of pediatric anxiety disorders | |
| US20090005367A1 (en) | Composition and method for treating alcoholism and other substance addictions | |
| Naderi-Heiden et al. | Effect of intravenous magnesium sulphate in reducing irritability and restlessness in pure and polysubstance opiate detoxification | |
| Kanchan et al. | Medical Treatment of Alcohol Dependence | |
| EP4422629A1 (en) | Treatment of major depressive disorder | |
| Standridge et al. | The clinical realities of using drugs to fight alcoholism. | |
| AU2006246490B8 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |